CCS Guideline Development Process
CCS is committed to developing statements that are high quality and transparent. In addition to the CCS specific procedures and policies, CCS follows the AGREE II Instrument as an overarching methodology to guide development and has adopted the GRADE Scale for rating the strength of recommendations and the quality of evidence.
The following documents describe the policies and procedures for development of guidelines and clinical practice updates.
Addresses all policies and procedures related to the CCS guideline development process including topic selection, panel selection, evidence review, defining and achieving consensus, statement format, approval process, CCC presentation and CJC publication.
Outlines the policies and procedures that guide CCS and its affiliates in the development of Clinical Practice Updates (CPUs), including the processes of topic selection, co-chair selection, panel formation, format, review, approval, and submission to the CJC.
CCS GRADE Framework
To ensure high quality and transparency, the CCS has adopted the GRADE Scale for rating the strength of recommendations and the quality of evidence. As of January 2010, the CCS has used the GRADE system of evidence assessment for all guidelines and position statements. In June 2015, CCS developed a GRADE Framework to provide an overview of the systematic review of evidence and the application of GRADE when developing recommendations.
For more information on GRADE, please refer to the BMJ GRADE primer articles below:
Part 1 – GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Part 2 – GRADE: what is “quality of evidence” and why is it important to clinicians?
Part 3 – GRADE: going from evidence to recommendations
Part 4 – GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Part 5 – GRADE: Incorporating considerations of resources use into grading recommendations
Part 6 – GRADE: Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive
Guidelines and Statements Currently Under Development
|Guidelines and Statements Title||Co-Chairs||Expected Completion|
|CCS/CACHnet Guidelines for the Management of Adults|
with Congenital Heart Disease
|CCS/CanCare/CNCS Position Statement on Neurologic |
Prognostication in the Post Cardiac Arrest Patient
|CCS Clinical Practice Update on Measuring Long QTc||R. Davies|
|CCS/CPCA Clinical Practice Update on the Screening and Management of Lipid Disorders in Children and Adolescents||B. McCrindle|
|CCS/CHFS Clinical Practice Update: HF Phenotype Pathway||S. Zieroth||2022|
|CCS Guidelines for use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults||J. Mancini|
|CCS Guidelines on the Fitness to Drive and Fly||P. Guerra|
|CCS/CSE Position Statement on Indications and Appropriate Use of Echocardiography in Canada||H. Leong-Poi|
|CCS/CANCARE/CSCS Guidelines on Post-Operative Critical Care Management of Patients Undergoing Cardiac Surgery||A. Hassan|
S. van Diepen
|CCS Clinical Practice Update on Smoking Cessation and the Cardiovascular Specialist||A. Pipe|
|CCS Clinical Practice Update on Cardiac Tumors||R. Cusimano|
|CCS Guidelines on Presentation, Diagnosis, and Medical Update of the Management of Heart Failure in Children||A. Jeewa|
|CCS/CAIC Focused Update of the Guidelines for the Use of Antiplatelet Therapy||K. Bainey|
|CCS/CSCS/CSVS/CAIR CPU: The Aortic Team Model and Collaborative Decision Pathways for the Management of Complex Aortic Disease -A Multi-Society Expert Consensus||S. McClure||2023|
|CCS Clinical Practice Update on the Contemporary Management of the Patient with Hypertrophic Cardiomyopathy||A. Crean|
|CCS/Canadian Women’s Heart Health Alliance (CWHHA) Clinical Practice Update on Myocardial Infarction with No Obstructive Coronary Artery Disease (MINOCA)||C. Pacheco|